Clinical Trial

Adjuvant Benmelstobart for Stage IB, Grade 3 Invasive Lung Adenocarcinoma

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This study is a prospective, single-arm, phase 2 clinical trial assessing the feasibility, efficacy, and safety of the PD-L1 inhibitor Benmelstobart (TQB2450) as an adjuvant therapy regimen in patients with pathologic stage IB, IASLC grade 3 invasive lung adenocarcinoma without EGFR active mutations or ALK rearrangement.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2024-07-26.
Trial Details
NCT Number NCT06528847
Lead Sponsor Shanghai Pulmonary Hospital, Shanghai, China
Conditions Non-Small Cell Lung Cancer
Enrollment 62 participants
Start Date 2024-06-05
Primary Completion 2027-06-30 (estimated)
Study Completion 2030-06-30 (estimated)
Updated on ClinicalTrials.gov 2024-07-31